Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer

被引:530
|
作者
van Meerbeeck, Jan P.
Kramer, Gijs W. P. M.
Van Schil, Paul E. Y.
Legrand, Catherine
Smit, Egbert F.
Schramel, Franz
Tjan-Heijnen, Vivianne C.
Biesma, Bonne
Debruyne, Channa
van Zandwijk, Nico
Splinter, Ted A. W.
Giaccone, Giuseppe
机构
[1] Ghent Univ Hosp, Dept Resp Med, B-9000 Ghent, Belgium
[2] Arnhem Radiotherapeut Inst, Dept Radiat Therapy, Arnhem, Netherlands
[3] Univ Hosp Antwerp, Dept Resp Med, Antwerp, Belgium
[4] Univ Hosp Antwerp, Dept Thorac Surg, Antwerp, Belgium
[5] European Org Res Treatment Canc, Ctr Data, Brussels, Belgium
[6] Vrije Univ Amsterdam, Dept Pulmonol, Amsterdam, Netherlands
[7] Vrije Univ Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
[8] St Antonius Hosp, Dept Pulmonol, Nieuwegein, Netherlands
[9] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[10] Jeroen Bosch Ziekenhuis, Dept Pulmonol, Shertogenbosch, Netherlands
[11] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[12] Erasmus MC, Dept Pulmonol, Rotterdam, Netherlands
[13] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands
来源
关键词
D O I
10.1093/jnci/djk093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Induction chemotherapy before surgical resection increases survival compared with surgical resection alone in patients with stage IIIA-N2 non-small-cell lung cancer (NSCLC). We hypothesized that, following a response to induction chemotherapy, surgical resection would be superior to thoracic radiotherapy as locoregional therapy. Methods Selected patients with histologic or cytologic proven stage IIIA-N2 NSCLC were given three cycles of platinum-based induction chemotherapy. Responding patients were subsequently randomly assigned to surgical resection or radiotherapy. Survival curves were estimated using Kaplan-Meier analyses from time of randomization. Results Induction chemotherapy resulted in a response rate of 61% (95% confidence interval [Cl] = 57% to 65%) among the 579 eligible patients. A total of 167 patients were allocated to resection and 165 to radiotherapy. Of the 154 (92%) patients who underwent surgery, 14% had an exploratory thoracotomy, 50% a radical resection, 42% a pathologic downstaging, and 5% a pathologic complete response; 4% died after surgery. Postoperative radiotherapy was administered to 62 (40%) of patients in the surgery arm. Among the 154 (93%) irradiated patients, overall compliance to the radiotherapy prescription was 55%, and grade 3/4 acute and late esophageal and pulmonary toxic effects occurred in 4% and 7%; one patient died of radiation pneumonitis. Median and 5-year overall survival for patients randomly assigned to resection versus radiotherapy were 16.4 versus 17.5 months and 15.7% versus 14%, respectively (hazard ratio = 1.06, 95% Cl = 0.84 to 1.35). Rates of progression-free survival were also similar in both groups. Conclusion In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiotherapy. In view of its low morbidity and mortality, radiotherapy should be considered the preferred locoregional treatment for these patients.
引用
收藏
页码:442 / 450
页数:9
相关论文
共 50 条
  • [21] A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941)
    van Meerbeeck, J
    Van Schil, P
    Kramer, G
    Legrand, C
    O'Brien, M
    Manegold, C
    Passioukov, A
    Giaccone, G
    van Zandwijk, N
    Splinter, T
    LUNG CANCER, 2005, 49 : S4 - S4
  • [22] Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
    Senan, S.
    Ozguroglu, M.
    Daniel, D.
    Villegas, A.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Faivre-Finn, C.
    Paz-Ares, L.
    Wu, Y. L.
    Mann, H.
    Dennis, P. A.
    Antonia, S. J.
    ESMO OPEN, 2022, 7 (02)
  • [23] A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941)
    van Meerbeeck, J.
    Kramer, G.
    Van Schil, P.
    Legrand, C.
    Passioukov, A.
    O'Brien, M.
    van Zandwijk, N.
    Giaccone, G.
    Manegold, C.
    Splinter, T.
    EJC SUPPLEMENTS, 2005, 3 (02): : 323 - 323
  • [24] Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer
    Selek, Ugur
    Chang, Joe Y.
    JOURNAL OF THORACIC DISEASE, 2016, 8 (07) : 1394 - 1397
  • [25] Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer
    Mathisen, DJ
    Wain, JC
    Wright, C
    Choi, N
    Carey, R
    Hilgenberg, A
    Grossbard, M
    Lynch, T
    Grillo, H
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (01): : 123 - 131
  • [26] Postoperative radiotherapy in non-small cell lung cancer stage IIIA-N2: Focus and perspectives
    Wang, Pascal
    Duchemann, Boris
    Chouahnia, Kader
    Matton, Lise
    Benabadji, Ambre
    Zelek, Laurent
    Popotte, Hosni
    Paix, Adrien
    BULLETIN DU CANCER, 2023, 110 (01) : 101 - 112
  • [28] Postoperative Radiotherapy in Completely Resected Stage IIIA-N2 Non-Small Cell Lung Cancer
    Ahn, S.
    Na, K.
    Kim, Y.
    Song, S.
    Oh, I.
    Park, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2180 - S2181
  • [29] Preresectional chemotherapy in stage IIIA non-small-cell lung cancer:: a 7-year assessment of a randomized controlled trial
    Rosell, R
    Gómez-Codina, J
    Camps, C
    Sánchez, JJ
    Maestre, J
    Padilla, J
    Cantó, A
    Abad, A
    Roig, J
    LUNG CANCER, 1999, 26 (01) : 7 - 14
  • [30] Risk Associated with Bilobectomy after Neoadjuvant Concurrent Chemoradiotherapy for Stage IIIA-N2 Non-small-cell Lung Cancer
    Jong Ho Cho
    Jhingook Kim
    Kwhanmien Kim
    Young Mog Shim
    Hong Kwan Kim
    Yong Soo Choi
    World Journal of Surgery, 2012, 36 : 1199 - 1205